Prospects for new antibacterials: can we do better?

Area of Science:

• Microbiology
• Pharmacology
• Infectious Diseases

Background:

• Bacterial resistance to antibiotics, including MRSA, VRE, and CRE, has escalated significantly.
• Multidrug-resistant Gram-negative bacteria like Pseudomonas aeruginosa and Acinetobacter baumannii pose increasing threats.
• Declining R&D investment in antibacterials has created a drug discovery gap, particularly for Gram-negative pathogens.

Purpose of the Study:

• To highlight the urgent need for new antibacterial strategies.
• To emphasize the critical gap in developing drugs against Gram-negative bacteria.
• To advocate for innovative approaches and collaborative research models.

Main Methods:

• Review of current trends in antibacterial resistance.
• Analysis of the R&D landscape in antibacterial drug discovery.
• Examination of the challenges and opportunities in developing new antibiotics.

Main Results:

• Existing drug development pipelines primarily focus on Gram-positive bacteria, neglecting Gram-negative threats.
• Financial constraints have limited pharmaceutical R&D, with small biotech firms struggling to fill the void.
• A significant need exists for first-in-class antibacterials and novel therapeutic targets.

Conclusions:

• Urgent focus is required on developing antibacterials targeting Gram-negative bacteria, especially enterobacteria.
• Enhanced transparency and careful clinical development are crucial for new antibacterial agents.
• Public-private partnerships are essential to foster innovation, ensure long-term stability, and balance stakeholder interests in antibacterial R&D.